IDEAS home Printed from https://ideas.repec.org/r/eee/jhecon/v22y2003i2p151-185.html
   My bibliography  Save this item

The price of innovation: new estimates of drug development costs

Citations

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Sam Watson’s journal round-up for 4th April 2016
    by Sam Watson in The Academic Health Economists' Blog on 2016-04-04 16:00:24

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Rong, Rong & Houser, Daniel, 2015. "Growing stars: A laboratory analysis of network formation," Journal of Economic Behavior & Organization, Elsevier, vol. 117(C), pages 380-394.
  2. Dosi, Giovanni & Palagi, Elisa & Roventini, Andrea & Russo, Emanuele, 2023. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," Journal of Economic Behavior & Organization, Elsevier, vol. 212(C), pages 564-589.
  3. Xiaoqing Li & Yu Zheng & Catherine L. Wang, 2016. "Inter-firm collaboration in new product development in Chinese pharmaceutical companies," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 165-193, March.
  4. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
  5. Michele Samorani & Manuel Laguna & Robert Kirk DeLisle & Daniel C. Weaver, 2011. "A Randomized Exhaustive Propositionalization Approach for Molecule Classification," INFORMS Journal on Computing, INFORMS, vol. 23(3), pages 331-345, August.
  6. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013. "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94, Springer.
  7. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
  8. Raphael Greiner & Siah Ang, 2012. "Biotechnology collaborations: does business model matter?," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 377-392, August.
  9. Lo Nigro, Giovanna & Perrone, Giovanni & Chiapparrone, Silvia, 2012. "Governance forms drivers in bio-pharmaceutical inter-firm relationships," International Journal of Production Economics, Elsevier, vol. 140(2), pages 604-613.
  10. Tannistra Banerjee & Stephen Martin, 2015. "Pharmaceutical Regulation and Innovative Performance: A Decision‐theoretic Model," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 36(3), pages 177-190, April.
  11. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," Journal of Economic Perspectives, American Economic Association, vol. 25(2), pages 27-46, Spring.
  12. Garcia-Goni, Manuel & Maroto, Andres & Rubalcaba, Luis, 2007. "Innovation and motivation in public health professionals," Health Policy, Elsevier, vol. 84(2-3), pages 344-358, December.
  13. Alexandre Guimarães Vasconcellos & Carlos Medicis Morel, 2012. "Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil," PLOS ONE, Public Library of Science, vol. 7(10), pages 1-10, October.
  14. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
  15. Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
  16. Pronker, Esther & Weenen, Tamar & Commandeur, Harry & Claassen, E. & Osterhaus, A.D.M.E., 2015. "Scratching the surface: Exploratory analysis of key opinion leaders on rate limiting factors in novel adjuvanted-vaccine development," Technological Forecasting and Social Change, Elsevier, vol. 90(PB), pages 420-432.
  17. Kehrig, Matthias & Vincent, Nicolas, 2019. "Good Dispersion, Bad Dispersion," CEPR Discussion Papers 13772, C.E.P.R. Discussion Papers.
  18. Ralph S. J. Koijen & Tomas J. Philipson & Harald Uhlig, 2016. "Financial Health Economics," Econometrica, Econometric Society, vol. 84, pages 195-242, January.
  19. Stephane Régnier, 2013. "What is the value of ‘me-too’ drugs?," Health Care Management Science, Springer, vol. 16(4), pages 300-313, December.
  20. Bradley T. Shapiro, 2016. "Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR," Quantitative Marketing and Economics (QME), Springer, vol. 14(3), pages 201-231, September.
  21. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
  22. Darren Filson & Neal Masia, 2007. "Effects of profit-reducing policies on firm survival, financial performance, and new drug introductions in the research-based pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 329-351.
  23. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
  24. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
  25. Frank Windmeijer & Eric de Laat & Rudy Douven & Esther Mot, 2006. "Pharmaceutical promotion and GP prescription behaviour," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 5-18, January.
  26. Chorniy, Anna & Bailey, James & Maloney, Michael & Civan, Abdulkadir, 2019. "Regulatory Review Time and Pharmaceutical R&D," Working Papers 06923, George Mason University, Mercatus Center.
  27. John Romley & Tiffany Shih, 2017. "Product safety spillovers and market viability for biologic drugs," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 135-158, June.
  28. Marcus T. Wolfe & Dean A. Shepherd, 2015. "What do you have to Say about That? Performance Events and Narratives’ Positive and Negative Emotional Content," Entrepreneurship Theory and Practice, , vol. 39(4), pages 895-925, July.
  29. Carolin Häussler & Hans-Martin Zademach, 2007. "Cluster Performance Reconsidered: Structure, Linkages and Paths in the German Bioteehnology Industry, 1996-2003," Schmalenbach Business Review (sbr), LMU Munich School of Management, vol. 59(3), pages 261-281, July.
  30. Filson, Darren & Oweis, Ahmed, 2010. "The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(4), pages 575-584, July.
  31. Wittmann, Nadine, 2014. "Economic reasoning on the correlation between life expectancy and economic development: Exploring alternative routes," Economics Discussion Papers 2014-43, Kiel Institute for the World Economy (IfW Kiel).
  32. Hermans, Raine & Kulvik, Martti, 2005. "Initiatives on a Sustainable Development Strategy for Finnish Biotechnology," Discussion Papers 988, The Research Institute of the Finnish Economy.
  33. Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
  34. Dennys Eduardo Rossetto & Roberto Carlos Bernardes & Felipe Mendes Borini & Cristiane Chaves Gattaz, 2018. "Structure and evolution of innovation research in the last 60 years: review and future trends in the field of business through the citations and co-citations analysis," Scientometrics, Springer;Akadémiai Kiadó, vol. 115(3), pages 1329-1363, June.
  35. Stefano Capri & Rosella Levaggi, 2005. "Reconciling social and industrial goals: a bargaining model to pricing pharmaceuticals," LIUC Papers in Economics 170, Cattaneo University (LIUC).
  36. C. Scott Hemphill & Bhaven N. Sampat, 2012. "Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals," NBER Chapters, in: Standards, Patents and Innovations, National Bureau of Economic Research, Inc.
  37. Malueg, David A. & Snyder, Christopher M., 2006. "Bounding the relative profitability of price discrimination," International Journal of Industrial Organization, Elsevier, vol. 24(5), pages 995-1011, September.
  38. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  39. Winghan Kwong & Edward Norton, 2007. "The Effect of Advertising on Pharmaceutical Innovation," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 221-236, November.
  40. Grinols, Earl L. & Lin, Hwan C., 2011. "Patent replacement and welfare gains," Journal of Economic Dynamics and Control, Elsevier, vol. 35(9), pages 1586-1604, September.
  41. Ernst R. Berndt & Joseph P. Newhouse, 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," NBER Working Papers 16297, National Bureau of Economic Research, Inc.
  42. Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
  43. Klaus S. Friesenbichler & Gerhard Schwarz, 2009. "Eine qualitative Abschätzung der Auswirkungen der Biopatentrichtlinie auf die Wirtschafts- und Forschungspolitik in Österreich," WIFO Studies, WIFO, number 36041, January.
  44. Thomas A. Abbott & John A. Vernon, 2005. "The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions," NBER Working Papers 11114, National Bureau of Economic Research, Inc.
  45. Holger Patzelt & Dean A. Shepherd, 2009. "Strategic Entrepreneurship at Universities: Academic Entrepreneurs’ Assessment of Policy Programs," Entrepreneurship Theory and Practice, , vol. 33(1), pages 319-340, January.
  46. Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
  47. Rose.Janna L. & Quave, Cassandra L. & Islam, Gazi, 2011. "The Four-Sided Triangle of Ethics in Bioprospecting: Pharmaceutical Business, International Politics, Socio-Environmental Responsibility and the Importance of Local Stakeholders," Insper Working Papers wpe_267, Insper Working Paper, Insper Instituto de Ensino e Pesquisa.
  48. Drechsler, Wenzel & Natter, Martin, 2012. "Understanding a firm's openness decisions in innovation," Journal of Business Research, Elsevier, vol. 65(3), pages 438-445.
  49. Ng, Desmond W., 2011. "Thinking Outside the Box: An Absorptive Capacity Approach to the Product Development Process," International Food and Agribusiness Management Review, International Food and Agribusiness Management Association, vol. 14(3), pages 1-28, September.
  50. Jung Ho Park & Kwangsoo Shin, 2018. "R&D Project Valuation Considering Changes of Economic Environment: A Case of a Pharmaceutical R&D Project," Sustainability, MDPI, vol. 10(4), pages 1-15, March.
  51. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
  52. Desmond Sheridan & Jim Attridge, 2006. "The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine," PharmacoEconomics, Springer, vol. 24(2), pages 35-54, December.
  53. Kristopher J. Hult, 2017. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments," NBER Working Papers 23900, National Bureau of Economic Research, Inc.
  54. Joan Farre‐Mensa & Deepak Hegde & Alexander Ljungqvist, 2020. "What Is a Patent Worth? Evidence from the U.S. Patent “Lottery”," Journal of Finance, American Finance Association, vol. 75(2), pages 639-682, April.
  55. Christian Zeller & Andreas Hametner & Koen Smet & Markus Seiwald, 2014. "Internationale Expansion in der pharmazeutischen Industrie Österreichs," FIW Research Reports series V-004, FIW.
  56. Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022. "The economics of medical procedure innovation," Journal of Health Economics, Elsevier, vol. 81(C).
  57. Bardey, D. & Bommier, A. & Jullien, B., 2010. "Retail price regulation and innovation: Reference pricing in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(2), pages 303-316, March.
  58. Ming Liu & Sumner la Croix, 2013. "A Cross-Country Index of Intellectual Property Rights in Pharmaceutical Innovations," Working Papers 201313, University of Hawaii at Manoa, Department of Economics.
  59. Dean Baker, 2007. "Stagnation in the Drug Development Process: Are Patents the Problem?," CEPR Reports and Issue Briefs 2007-07, Center for Economic and Policy Research (CEPR).
  60. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany.
  61. Hong, Suckwon & Kim, Juram & Woo, Han-Gyun & Kim, Young-Choon & Lee, Changyong, 2022. "Screening ideas in the early stages of technology development: A word2vec and convolutional neural network approach," Technovation, Elsevier, vol. 112(C).
  62. Marcela Miozzo & Lori DiVito & Panos Desyllas, 2011. "Cross-border acquisitions of science-based firms: Their effect on innovation in the acquired firm and the local science," DRUID Working Papers 11-17, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
  63. Henry G. Grabowski & Margaret Kyle, 2007. "Generic competition and market exclusivity periods in pharmaceuticals," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 491-502.
  64. Keng, Ying Ying & Kwa, Kiam Heong & Ratnavelu, Kurunathan, 2021. "Centrality analysis in a drug network and its application to drug repositioning," Applied Mathematics and Computation, Elsevier, vol. 395(C).
  65. Tannista Banerjee & Ralph Siebert, 2013. "The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry," Auburn Economics Working Paper Series auwp2013-20, Department of Economics, Auburn University.
  66. Aleksey Tetenov, 2016. "An economic theory of statistical testing," CeMMAP working papers CWP50/16, Centre for Microdata Methods and Practice, Institute for Fiscal Studies.
  67. Kristopher J. Hult, 2018. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 185-216, National Bureau of Economic Research, Inc.
  68. Costello, Christopher & Ward, Michael, 2006. "Search, bioprospecting and biodiversity conservation," Journal of Environmental Economics and Management, Elsevier, vol. 52(3), pages 615-626, November.
  69. Benjamin Speich & Nadine Schur & Dmitry Gryaznov & Belinda von Niederhäusern & Lars G Hemkens & Stefan Schandelmaier & Alain Amstutz & Benjamin Kasenda & Christiane Pauli-Magnus & Elena Ojeda-Ruiz & Y, 2019. "Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-16, January.
  70. Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
  71. Clara I. Gonzalez & Ricardo Gimeno, 2008. "Financial Analysts impact on Stock Volatility. A Study on the Pharmaceutical Sector," Working Papers 2008-19, FEDEA.
  72. Michael R. Darby & Lynne G. Zucker, 2006. "Innovation, Competition and Welfare-Enhancing Monopoly," NBER Working Papers 12094, National Bureau of Economic Research, Inc.
  73. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
  74. C. Scott Hemphill & Bhaven N. Sampat, 2011. "When Do Generics Challenge Drug Patents?," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 8(4), pages 613-649, December.
  75. Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.
  76. Joshua S. Gans & David B. Ridley, 2013. "Innovation Incentives under Transferable Fast-Track Regulatory Review," Journal of Industrial Economics, Wiley Blackwell, vol. 61(3), pages 789-816, September.
  77. Tim Swift, 2016. "The perilous leap between exploration and exploitation," Strategic Management Journal, Wiley Blackwell, vol. 37(8), pages 1688-1698, August.
  78. Martin, Ralf & Thomas, Catherine & Mohnen, Pierre & Verhoeven, Dennis & Guillard, Charlotte, 2021. "Efficient Industrial Policy for Innovation: Standing on the shoulders of Hidden Giants," CEPR Discussion Papers 16850, C.E.P.R. Discussion Papers.
  79. Jeffrey Clemens & Stan Veuger, 2015. "Risks to the Returns to Medical Innovation: The Case of Myriad Genetics," NBER Working Papers 21469, National Bureau of Economic Research, Inc.
  80. Philip Sauré, 2015. "The Resilient Trade Surplus, the Pharmaceutical Sector, and Exchange Rate Assessments in Switzerland," Working Paper Series WP15-11, Peterson Institute for International Economics.
  81. Haim V. Levy, 2012. "Transferability and Commercialization of Patent Rights: Economic and Practical Perspectives," Journal of Entrepreneurship, Management and Innovation, Fundacja Upowszechniająca Wiedzę i Naukę "Cognitione", vol. 8(2), pages 44-59.
  82. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
  83. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
  84. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
  85. John Urquhart, 2003. "Editorial: How long do pharmaceuticals stay in the market‐place?," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 166(3), pages 274-277, October.
  86. Vernon, John A. & Golec, Joseph H. & Lutter, Randall & Nardinelli, Clark, 2009. "An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending," The Quarterly Review of Economics and Finance, Elsevier, vol. 49(4), pages 1260-1274, November.
  87. Nathalie Vernaz & François Girardin & Nicolas Goossens & Urs Brügger & Marco Riguzzi & Arnaud Perrier & Francesco Negro, 2016. "Drug Pricing Evolution in Hepatitis C," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-12, June.
  88. John A. Vernon, 2006. "The Future of Drug Development: the Economics of Pharmacogenomics," Working Papers id:589, eSocialSciences.
  89. Nishimura, Junichi & Okada, Yosuke, 2014. "R&D portfolios and pharmaceutical licensing," Research Policy, Elsevier, vol. 43(7), pages 1250-1263.
  90. K D S Fernald & H P G Pennings & J F van den Bosch & H R Commandeur & E Claassen, 2017. "The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-22, February.
  91. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
  92. Lo Nigro, Giovanna & Morreale, Azzurra & Enea, Gianluca, 2014. "Open innovation: A real option to restore value to the biopharmaceutical R&D," International Journal of Production Economics, Elsevier, vol. 149(C), pages 183-193.
  93. Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
  94. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
  95. Hein, Wolfgang & Kohlmorgen, Lars, 2005. "Global Health Governance: Conflicts on Global Social Rights," GIGA Working Papers 7, GIGA German Institute of Global and Area Studies.
  96. Adrian Towse, 2007. "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 653-665, July.
  97. Mc Namara, Peter & Baden-Fuller, Charles, 2007. "Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms," Research Policy, Elsevier, vol. 36(4), pages 548-565, May.
  98. Martin, Ralf & Thomas, Catherine & Mohnen, Pierre & Verhoeven, Dennis & Guillard, Charlotte, 2021. "Efficient Industrial Policy for Innovation: Standing on the shoulders of Hidden Giants," CEPR Discussion Papers 16850, C.E.P.R. Discussion Papers.
  99. Giulia Trombini & Anna Comacchio, 2012. "Cooperative Markets for Ideas: When does Technology Licensing Combine with R&D Partnerships?," Working Papers 8, Department of Management, Università Ca' Foscari Venezia.
  100. Gary J. Summers, 2021. "Friction and Decision Rules in Portfolio Decision Analysis," Decision Analysis, INFORMS, vol. 18(2), pages 101-120, June.
  101. Natalie Chun & Minjung Park, 2013. "The impact of health insurance mandates on drug innovation: evidence from the United States," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 323-344, April.
  102. Michele Boldrin & David K. Levine, 2013. "The Case against Patents," Journal of Economic Perspectives, American Economic Association, vol. 27(1), pages 3-22, Winter.
  103. Mark Duggan & Fiona Scott Morton, 2010. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.
  104. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
  105. Anita Rao, 2020. "Strategic Research and Development Investment Decisions in the Pharmaceutical Industry," Marketing Science, INFORMS, vol. 39(3), pages 564-586, May.
  106. Sean M. Dougherty & Robert Inklaar & Robert H. McGuckin & Bart van Ark, 2007. "International Comparisons of R&D Expenditure: Does an R&D PPP Make a Difference?," NBER Chapters, in: Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches, pages 291-322, National Bureau of Economic Research, Inc.
  107. Andrew F Christie & Chris Dent & Peter McIntyre & Lachlan Wilson & David M Studdert, 2013. "Patents Associated with High-Cost Drugs in Australia," PLOS ONE, Public Library of Science, vol. 8(4), pages 1-7, April.
  108. Adrian Towse & Priya Sharma, 2011. "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 331-350.
  109. Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
  110. Lang, Hui-Chu & Scheffler, Richard M. & Hu, Teh-wei, 2010. "The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--A global pharmaceutical data analysis," Health Policy, Elsevier, vol. 97(1), pages 71-78, September.
  111. Qing Ye & Chang-Yu Hsieh & Ziyi Yang & Yu Kang & Jiming Chen & Dongsheng Cao & Shibo He & Tingjun Hou, 2021. "A unified drug–target interaction prediction framework based on knowledge graph and recommendation system," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
  112. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
  113. Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
  114. Garavaglia Christian & Malerba Franco & Orsenigo Luigi & Pezzoni Michele, 2014. "Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 234(2-3), pages 274-298, April.
  115. Marc Herz & Nicco Krezdorn, 2022. "Epic fail: Exploring project failure’s reasons, outcomes and indicators," Review of Managerial Science, Springer, vol. 16(4), pages 1169-1193, May.
  116. Liu, Ming & La Croix, Sumner, 2015. "A cross-country index of intellectual property rights in pharmaceutical inventions," Research Policy, Elsevier, vol. 44(1), pages 206-216.
  117. William S. Comanor & Stuart O. Schweitzer, 2007. "Determinants of drug prices and expenditures," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 357-370.
  118. Anna-Maria Aksan, 2013. "Appropriate Health R&D and Intellectual Property Rights Reform in Developing Countries," Economica, London School of Economics and Political Science, vol. 80(319), pages 475-495, July.
  119. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2009. "Nuove politiche per l'innovazione nel settore delle scienze della vita," Working Papers CERM 03-2009, Competitività, Regole, Mercati (CERM).
  120. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, Oxford University Press, vol. 119(3), pages 1049-1090.
  121. Gleason, Katherine I. & Klock, Mark, 2006. "Intangible capital in the pharmaceutical and chemical industry," The Quarterly Review of Economics and Finance, Elsevier, vol. 46(2), pages 300-314, May.
  122. Kunter Gunasti & Hans Baumgartner, 2016. "The Asymmetric Effects of Positive Or Negative Experiences with an Extension on Low- or High-Equity Parent Brands: A Microtheoretical Notion," Customer Needs and Solutions, Springer;Institute for Sustainable Innovation and Growth (iSIG), vol. 3(3), pages 126-143, December.
  123. Mathias Kifmann & Sven Neelsen, 2010. "Germany's Struggle with Prices for Patent-protected Drugs," ifo DICE Report, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, vol. 8(3), pages 43-52, October.
  124. Atanassov, Atanas & Bahieldin, Ahmed & Brink, Johan & Burachik, Moises & Cohen, Joel I. & Dhawan, Vibha & Ebora, Reynaldo V. & Falck-Zepeda, José & Herrera-Estrella, Luis & Komen, John & Chon Low, Fee, 2004. "To reach the poor: results from the ISNAR-IFPRI Next Harvest study on genetically modified crops, public research, and policy implications," EPTD discussion papers 116, International Food Policy Research Institute (IFPRI).
  125. Christian Schröder, 2009. "Financial System and Innovations-Determinants of Early Stage Venture Capital in Europe," Schumpeter Discussion Papers sdp09004, Universitätsbibliothek Wuppertal, University Library.
  126. Joan Costa-Font & Alistair McGuire & Nebibe Varol, 2015. "Regulation effects on the adoption of new medicines," Empirical Economics, Springer, vol. 49(3), pages 1101-1121, November.
  127. Ilan Guedj & David Scharfstein, 2004. "Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms," NBER Working Papers 10933, National Bureau of Economic Research, Inc.
  128. Grillitsch, Markus & Schubert, Torben & Srholec, Martin, 2019. "Knowledge base combinations and firm growth," Research Policy, Elsevier, vol. 48(1), pages 234-247.
  129. Gamba, Simona, 2017. "The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector," World Development, Elsevier, vol. 99(C), pages 15-27.
  130. Pascale Crama & Bert De Reyck & Zeger Degraeve & Wang Chong, 2007. "Research and Development Project Valuation and Licensing Negotiations at Phytopharm plc," Interfaces, INFORMS, vol. 37(5), pages 472-487, October.
  131. Joseph Golec & John Vernon, 2010. "Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms," PharmacoEconomics, Springer, vol. 28(8), pages 615-628, August.
  132. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
  133. Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
  134. Jacoline Bouvy & Just Weemers & Huub Schellekens & Marc Koopmanschap, 2011. "Willingness to Pay for Adverse Drug Event Regulatory Actions," PharmacoEconomics, Springer, vol. 29(11), pages 963-975, November.
  135. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.
  136. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Leibniz Centre for European Economic Research.
  137. Corinne Sauer & Robert Sauer, 2007. "Is it possible to have cheaper drugs and preserve the incentive to innovate? The benefits of privatizing the drug approval process," The Journal of Technology Transfer, Springer, vol. 32(5), pages 509-524, October.
  138. Pedro Pita Barros & Xavier Martínez-Giralt, 2006. "On insurance and the cost-sharing of pharmaceutical R&D," Working Papers 293, Barcelona School of Economics.
  139. Christina M. L. Kelton & Robert P. Rebelein, 2007. "A General‐Equilibrium Analysis of Public Policy for Pharmaceutical Prices," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 9(2), pages 285-318, April.
  140. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
  141. Edward C. Mansley & Elamin H. Elbasha & Steven M. Teutsch & Marc L. Berger, 2007. "The Decision to Conduct a Head-to-Head Comparative Trial: A Game-Theoretic Analysis," Medical Decision Making, , vol. 27(4), pages 364-379, July.
  142. Erik Gronqvist & Douglas Lundin, 2009. "Incentives for clinical trials," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 18(5), pages 513-531.
  143. Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).
  144. Chellaraj, Gnanaraj & Maskus, Keith E. & Mattoo, Aaditya, 2005. "The contribution of skilled immigration and international graduate students to U.S. innovation," Policy Research Working Paper Series 3588, The World Bank.
  145. Jim Attridge, 2006. "Equity Of Access To Innovative Medicines: Mission Impossible?," Economic Affairs, Wiley Blackwell, vol. 26(3), pages 17-23, September.
  146. Joseph P. Cook & Graeme Hunter & John A. Vernon, 2010. "Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures," NBER Working Papers 15723, National Bureau of Economic Research, Inc.
  147. Patzelt, Holger & Behrens, Judith & Wolfe, Marcus T. & Shepherd, Dean A., 2020. "Perceived project transition support and employees' assessments of entrepreneurial project performance," Journal of Business Venturing, Elsevier, vol. 35(1).
  148. Ángel León & Diego Piñeiro, 2004. "Valuation of a Biotech Company: A Real Options Approach," Working Papers wp2004_0420, CEMFI.
  149. Pies, Ingo & Hielscher, Stefan, 2007. "Das Problem der internationalen Arzneimittelversorgung: Eine wirtschaftsethische Perspektive," Discussion Papers 2007-1, Martin Luther University of Halle-Wittenberg, Chair of Economic Ethics.
  150. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
  151. Ernst Berndt & Iain Cockburn & Karen Grépin, 2006. "The Impact of Incremental Innovation in Biopharmaceuticals," PharmacoEconomics, Springer, vol. 24(2), pages 69-86, December.
  152. Solon Moreira & Thomas Maximilian Klueter & Stefano Tasselli, 2020. "Competition, Technology Licensing-in, and Innovation," Organization Science, INFORMS, vol. 31(4), pages 1012-1036, July.
  153. Darren Filson & Saman Olfati & Fatos Radoniqi, 2015. "Evaluating Mergers in the Presence of Dynamic Competition Using Impacts on Rivals," Journal of Law and Economics, University of Chicago Press, vol. 58(4).
  154. Daniel R. Wilmoth, 2015. "Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1651-1656, December.
  155. Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
  156. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
  157. Sorisio, Enrico & Strøm, Steinar, 2006. "Innovation and market dynamics in the EPO market," Memorandum 12/2006, Oslo University, Department of Economics.
  158. Moshe Levy & Adi Rizansky, 2014. "Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 143-156, March.
  159. Livio Garattini & Alessandro Curto & Katelijne Vooren, 2015. "Western European markets for biosimilar and generic drugs: worth differentiating," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 683-687, September.
  160. Wagstaff, Adam & Culyer, Anthony J., 2012. "Four decades of health economics through a bibliometric lens," Journal of Health Economics, Elsevier, vol. 31(2), pages 406-439.
  161. Arisa Djurian & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs," Sustainability, MDPI, vol. 12(14), pages 1-14, July.
  162. Aleksey Tetenov, 2016. "An economic theory of statistical testing," CeMMAP working papers 50/16, Institute for Fiscal Studies.
  163. Joseph Golec & John Vernon, 2009. "Financial risk of the Biotech Industry versus the Pharmaceutical Industry," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 155-165, September.
  164. Oliver Baumann & Hariolf Grupp, 2008. "Firm boundary decisions: the market for health-related R&D services with an empirical case study for Germany," International Economics and Economic Policy, Springer, vol. 5(3), pages 297-321, November.
  165. Ljungqvist, Alexander & Farre-Mensa, Joan & Hegde, Deepak, 2016. "The Bright Side of Patents," CEPR Discussion Papers 11091, C.E.P.R. Discussion Papers.
  166. Yang, Guancan & Lu, Guoxuan & Xu, Shuo & Chen, Liang & Wen, Yuxin, 2023. "Which type of dynamic indicators should be preferred to predict patent commercial potential?," Technological Forecasting and Social Change, Elsevier, vol. 193(C).
  167. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
  168. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2010. "A History-Friendly Model of the Evolution of the Pharmaceutical Industry: Technological Regimes and Demand Structure," KITeS Working Papers 036, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Nov 2010.
  169. Céline Bérard & Marie Perez, 2014. "Alliance Dynamics through Real Options: The Case of an Alliance between Competing Pharmaceutical Companies," Post-Print hal-04010373, HAL.
  170. Grillitsch, Markus & Schubert, Torben & Srholec, Martin, 2016. "Knowledge diversity and firm growth: Searching for a missing link," Papers in Innovation Studies 2016/13, Lund University, CIRCLE - Centre for Innovation Research.
  171. Yaroslav Kryukov, "undated". "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.
  172. Heijs, Joost & Arenas Díaz, Guillermo & Vergara Reyes, Delia Margarita, 2019. "Impact of innovation on employment in quantitative terms: review of empirical literature based on microdata," MPRA Paper 95326, University Library of Munich, Germany.
  173. John A. Vernon & W. Keener Hughen, 2005. "The Future of Drug Development: The Economics of Pharmacogenomics," NBER Working Papers 11875, National Bureau of Economic Research, Inc.
  174. Fier, Andreas & Heneric, Oliver, 2005. "Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry," ZEW Discussion Papers 05-60, ZEW - Leibniz Centre for European Economic Research.
  175. Grewal, Rajdeep & Chakravarty, Anindita & Ding, Min & Liechty, John, 2008. "Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector," International Journal of Research in Marketing, Elsevier, vol. 25(4), pages 261-272.
  176. Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2009. "Trials, tricks and transparency: How disclosure rules affect clinical knowledge," Journal of Health Economics, Elsevier, vol. 28(6), pages 1141-1153, December.
  177. Engwall, Mats & Freilich, Jonatan, 2014. "Architectural Lock-in of the Drug Development Process," INDEK Working Paper Series 2014/4, Royal Institute of Technology, Department of Industrial Economics and Management.
  178. Joseph A. DiMasi & Henry G. Grabowski, 2007. "The cost of biopharmaceutical R&D: is biotech different?," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 469-479.
  179. Srivastava, Divya & McGuire, Alistair, 2014. "Analysis of prices paid by low-income countries: how price sensitive is government demand for medicines?," LSE Research Online Documents on Economics 60341, London School of Economics and Political Science, LSE Library.
  180. Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005. "Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances," Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
  181. Hirai, Yuka & Yamanaka, Yosuke & Kusama, Makiko & Ishibashi, Taro & Sugiyama, Yuichi & Ono, Shunsuke, 2012. "Analysis of the success rates of new drug development in Japan and the lag behind the US," Health Policy, Elsevier, vol. 104(3), pages 241-246.
  182. Mark Trusheim & Murray L. Aitken & Ernst R. Berndt, 2010. "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?," NBER Working Papers 16014, National Bureau of Economic Research, Inc.
  183. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
  184. Zhili Tian & Ralph Siebert, 2020. "Dynamic Effects of Licensing and Knowledge Transfer across Research Stages: Evidence from the Pharmaceutical Industry," CESifo Working Paper Series 8311, CESifo.
  185. Raymond J. March, 2021. "The FDA and the COVID‐19: A political economy perspective," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1210-1228, April.
  186. Comanor, William S. & Scherer, F.M., 2013. "Mergers and innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 32(1), pages 106-113.
  187. Entorf, Horst & Fegert, Jörg & Kölch, Michael, 2004. "Children in Need of Medical Innovation," Darmstadt Discussion Papers in Economics 135, Darmstadt University of Technology, Department of Law and Economics.
  188. Włodzimierz Sroka & Richard Szántó, 2018. "Corporate Social Responsibility and Business Ethics in Controversial Sectors: Analysis of Research Results," Journal of Entrepreneurship, Management and Innovation, Fundacja Upowszechniająca Wiedzę i Naukę "Cognitione", vol. 14(3), pages 111-126.
  189. Andreas Sturm & Michael J. Dowling & Klaus Röder, 2007. "FDA Drug Approvals: Time Is Money!," Journal of Entrepreneurial Finance, Pepperdine University, Graziadio School of Business and Management, vol. 12(2), pages 23-54, Fall.
  190. Bernhard Dachs & Klaus S. Friesenbichler & Martin Falk & Brigitte Nones, 2005. "Innovationsaktivitäten österreichischer Unternehmen im Ausland. Umfang, Motive und Auswirkungen auf Österreich," WIFO Studies, WIFO, number 28809, January.
  191. Frank, Richard G., 2003. "New estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 325-330, March.
  192. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
  193. Xuemin Gu & Nan Chen & Caimiao Wei & Suyu Liu & Vassiliki A. Papadimitrakopoulou & Roy S. Herbst & J. Jack Lee, 2016. "Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 8(1), pages 99-128, June.
  194. Enes Işık & Özgür Orhangazi, 2022. "Profitability and drug discovery," Industrial and Corporate Change, Oxford University Press, vol. 31(4), pages 891-904.
  195. Minyoung Kim & Curba Morris Lampert & Raja Roy, 2020. "Regionalization of R&D activities: (Dis)economies of interdependence and inventive performance," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 51(7), pages 1054-1075, September.
  196. Häussler, Carolin, 2006. "Can’t Buy Me Rights! The Contractual Structure of Asymmetrical Inter-firm Collaborations," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 189, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
  197. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
  198. Papachristos, George & Adamides, Emmanuel, 2016. "A retroductive systems-based methodology for socio-technical transitions research," Technological Forecasting and Social Change, Elsevier, vol. 108(C), pages 1-14.
  199. Joseph H. Golec & John A. Vernon, 2006. "European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending," NBER Working Papers 12676, National Bureau of Economic Research, Inc.
  200. Simone Ghislandi & Michael Kuhn, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Papers wuwp219, Vienna University of Economics and Business, Department of Economics.
  201. Shichun Xu & Erin Cavusgil & Seyda Deligonul, 2016. "Number Of R&D Alliances And Innovation Output — Nonlinear Relationship Evidence From The Pharmaceutical Industry," International Journal of Innovation Management (ijim), World Scientific Publishing Co. Pte. Ltd., vol. 20(06), pages 1-22, August.
  202. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
  203. Thakur-Wernz, Pooja & Bruyaka, Olga & Contractor, Farok, 2022. "Sourcing portfolio diversity in new product development: Antecedents and performance implications," Journal of Business Research, Elsevier, vol. 150(C), pages 179-193.
  204. Sauré, Philip, 2017. "Time-intensive R&D and unbalanced trade," European Economic Review, Elsevier, vol. 91(C), pages 229-244.
  205. Xiaoyang Xu & Adubofour Isaac & Lizhong Hao & Dandan Wang, 2019. "Investor Sentiment, Innovation Investment and Cash Dividend," International Journal of Economics and Finance, Canadian Center of Science and Education, vol. 11(7), pages 1-97, July.
  206. Edith Maes & Rutger Daems, 2011. "Perspectives on Public Private Partnership: The R&D Based Vaccine Industry," Working Papers 2011/36, Maastricht School of Management.
  207. repec:ebl:ecbull:v:6:y:2008:i:36:p:1-8 is not listed on IDEAS
  208. Dean Baker, 2016. "Publicly Funded Clinical Trials: A Route to Sustained Innovation with Affordable Drugs," CEPR Reports and Issue Briefs 2016-02, Center for Economic and Policy Research (CEPR).
  209. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.
  210. Raymond J. March, 2017. "Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 32(Fall 2017), pages 75-92.
  211. John A. Vernon & Joseph H. Golec & Joseph A. Dimasi, 2010. "Drug development costs when financial risk is measured using the Fama–French three‐factor model," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 1002-1005, August.
  212. Arnold, Denis G. & Amato, Louis H. & Troyer, Jennifer L. & Stewart, Oscar Jerome, 2022. "Innovation and misconduct in the pharmaceutical industry," Journal of Business Research, Elsevier, vol. 144(C), pages 1052-1063.
  213. Civan Abdulkadir & Maloney Michael T., 2009. "The Effect of Price on Pharmaceutical R&D," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(1), pages 1-24, April.
  214. Daniel B. Klein & Alexander Tabarrok, 2008. "Do Off‐Label Drug Practices Argue Against FDA Efficacy Requirements? A Critical Analysis of Physicians' Argumentation for Initial Efficacy Requirements," American Journal of Economics and Sociology, Wiley Blackwell, vol. 67(5), pages 743-775, November.
  215. Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck, 2006. "Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA," NBER Chapters, in: Innovation Policy and the Economy, Volume 6, pages 91-122, National Bureau of Economic Research, Inc.
  216. Christopher J. Longo, 2011. "Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries," International Journal of Development Issues, Emerald Group Publishing Limited, vol. 10(1), pages 92-101, April.
  217. Fernando Cruz Aranda & Antonia Terán Bustamante, 2019. "Valuation of an investment project in research and development in the pharmaceutical industry," Contaduría y Administración, Accounting and Management, vol. 64(1), pages 43-44, Enero-Mar.
  218. Malani, Anup & Philipson, Tomas J., 2011. "Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets," Working Papers 237, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
  219. Megan K. Meier, 2016. "Funding Research for Neglected Infectious Diseases: An Investment in the Future," International Journal of Sciences, Office ijSciences, vol. 5(07), pages 34-36, July.
  220. Eric Budish & Benjamin N. Roin & Heidi Williams, 2015. "Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials," American Economic Review, American Economic Association, vol. 105(7), pages 2044-2085, July.
  221. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
  222. Bérard, Céline & Perez, Marie, 2014. "Alliance dynamics through real options: The case of an alliance between competing pharmaceutical companies," European Management Journal, Elsevier, vol. 32(2), pages 337-349.
  223. Wagner, Stefan & Wakeman, Simon, 2016. "What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 45(5), pages 1091-1102.
  224. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  225. Ghauri, Pervez N. & Rao, P.M., 2009. "Intellectual property, pharmaceutical MNEs and the developing world," Journal of World Business, Elsevier, vol. 44(2), pages 206-215, April.
  226. Königbauer, Ingrid, 2006. "Dealing with Rising Health Care Costs: The Case of Pharmaceuticals," Munich Dissertations in Economics 5640, University of Munich, Department of Economics.
  227. Giaccotto, Carmelo & Golec, Joseph & Vernon, John, 2011. "New estimates of the cost of capital for pharmaceutical firms," Journal of Corporate Finance, Elsevier, vol. 17(3), pages 526-540, June.
  228. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
  229. Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
  230. König, Michael D. & Battiston, Stefano & Napoletano, Mauro & Schweitzer, Frank, 2012. "The efficiency and stability of R&D networks," Games and Economic Behavior, Elsevier, vol. 75(2), pages 694-713.
  231. Yin, Wesley, 2009. "R&D policy, agency costs and innovation in personalized medicine," Journal of Health Economics, Elsevier, vol. 28(5), pages 950-962, September.
  232. Waters, James, 2014. "Introduction of innovations during the 2007-8 financial crisis: US companies compared with universities," MPRA Paper 59016, University Library of Munich, Germany.
  233. Frank R. Lichtenberg, 2005. "Pharmaceutical Knowledge-Capital Accumulation and Longevity," NBER Chapters, in: Measuring Capital in the New Economy, pages 237-274, National Bureau of Economic Research, Inc.
  234. Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, May.
  235. Bunnik, Eline M. & Aarts, Nikkie & van de Vathorst, Suzanne, 2018. "Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs," Health Policy, Elsevier, vol. 122(9), pages 977-983.
  236. S. Perez-Vega & E. Ortega-Rivas & I. Salmeron-Ochoa & P. Sharratt, 2013. "A system view of solvent selection in the pharmaceutical industry: towards a sustainable choice," Environment, Development and Sustainability: A Multidisciplinary Approach to the Theory and Practice of Sustainable Development, Springer, vol. 15(1), pages 1-21, February.
  237. Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
  238. Natalia Leonidovna Borscheva & Yulia Vyacheslavovna Fedorova & Marina Ivanovna Glukhova & Guzal Ilgizovna Islamova, 2020. "Impact of innovative activity of organizations on the development of pharmaceutical industry: a case study," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 7(4), pages 3001-3015, June.
  239. Pedro Barros & Xavier Martinez-Giralt, 2008. "On international cost-sharing of pharmaceutical R&D," International Journal of Health Economics and Management, Springer, vol. 8(4), pages 301-312, December.
  240. Stephen Dunn, 2006. "Prolegomena to a Post Keynesian health economics," Review of Social Economy, Taylor & Francis Journals, vol. 64(3), pages 273-299.
  241. Haeussler, Carolin & Patzelt, Holger & Zahra, Shaker A., 2012. "Strategic alliances and product development in high technology new firms: The moderating effect of technological capabilities," Journal of Business Venturing, Elsevier, vol. 27(2), pages 217-233.
  242. Kenji Tomita, 2021. "Communication for Open Innovation in Japanese Drug Discovery Ventures," Journal of Management Sciences, Geist Science, Iqra University, Faculty of Business Administration, vol. 8(1), pages 36-49, March.
  243. Leiva Bertran, Fernando J. & Turner, John L., 2017. "Welfare-optimal patent royalties when imitation is costly," Journal of Economic Behavior & Organization, Elsevier, vol. 137(C), pages 457-475.
  244. Erin Cavusgil, 2007. "Merck and Vioxx: An Examination of an Ethical Decision-Making Model," Journal of Business Ethics, Springer, vol. 76(4), pages 451-461, December.
  245. Gnanaraj Chellaraj & Keith E. Maskus & Aaditya Mattoo, 2008. "The Contribution of International Graduate Students to US Innovation," Review of International Economics, Wiley Blackwell, vol. 16(3), pages 444-462, August.
  246. Stefano Tiziani & Alessia Lodi & Farhat L Khanim & Mark R Viant & Christopher M Bunce & Ulrich L Günther, 2009. "Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines," PLOS ONE, Public Library of Science, vol. 4(1), pages 1-10, January.
  247. Deepak Hegde, 2014. "Tacit Knowledge and the Structure of License Contracts: Evidence from the Biomedical Industry," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 23(3), pages 568-600, September.
  248. Jommi, Claudio & Paruzzolo, Silvia, 2007. "Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study," Health Policy, Elsevier, vol. 81(1), pages 117-130, April.
  249. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
  250. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
  251. Hyunju Rachel Kim, 2014. "Formulation of a Success Model in Pharmaceutical R&D," SAGE Open, , vol. 4(1), pages 21582440145, March.
  252. Jing-Yuan Chio & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2012. "The Value of Failures in Pharmaceutical R&D," Working Papers 1/2012, IMT School for Advanced Studies Lucca, revised Jan 2012.
  253. Dean Baker, 2008. "The Benefits and Savings of Publicly-Funded Clinical Trials of Prescription Drugs," CEPR Reports and Issue Briefs 2008-09, Center for Economic and Policy Research (CEPR).
  254. Brown, Austin R. & Wood, Matthew S. & Scheaf, David J., 2022. "Discovery sells, but who’s buying? An empirical investigation of entrepreneurs’ technology license decisions," Journal of Business Research, Elsevier, vol. 144(C), pages 403-415.
  255. Mansley Edward C & Teutsch Steven M & White Dawn M & Busza Jamie D & Geisel Steven S, 2008. "The Utilization of Medicines beyond Patent Expiration," Forum for Health Economics & Policy, De Gruyter, vol. 11(2), pages 1-21, November.
  256. Hanee Ryu & Hyejae Jung, 2021. "Impact of public R&D as market matures: Evidence from solar PV industry," Energy & Environment, , vol. 32(8), pages 1543-1558, December.
  257. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
  258. Muhammad Alshurideh & Barween Al Kurdi & Ala Abdullah Abumari & Said A. Salloum, 2018. "Pharmaceutical Promotion Tools Effect on Physician's Adoption of Medicine Prescribing: Evidence from Jordan," Modern Applied Science, Canadian Center of Science and Education, vol. 12(11), pages 210-210, November.
  259. Helga De Doncker, 2006. "R&D in the Belgian Pharmaceutical Sector," Working Paper Document 106, National Bank of Belgium.
  260. Michael Kremer & Christopher Snyder, 2004. "Why is There No AIDS Vaccine?," CID Working Papers 111, Center for International Development at Harvard University.
  261. Joseph Cook & Graeme Hunter & John Vernon, 2009. "The Future Costs, Risks and Rewards of Drug Development," PharmacoEconomics, Springer, vol. 27(5), pages 355-363, May.
  262. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2008. "Patent Value and R&D Competition," Working Papers 51/2008, University of Verona, Department of Economics.
  263. Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
  264. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
  265. Pedro Garcia-del-Barrio, 2017. "Pareto-improving income redistribution: expanding consumer access to the vaccines market," Economics of Governance, Springer, vol. 18(3), pages 275-313, August.
  266. Lampert, Curba Morris & Kim, Minyoung, 2019. "Going far to go further: Offshoring, exploration, and R&D performance," Journal of Business Research, Elsevier, vol. 103(C), pages 376-386.
  267. John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16, January.
  268. Trusheim Mark R. & Aitken Murray L. & Berndt Ernst R., 2010. "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?," Forum for Health Economics & Policy, De Gruyter, vol. 13(1), pages 1-45, July.
  269. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
  270. Massimo Riccaboni, 2012. "Is There a Productivity Crisis in Pharmaceutical R&D?," Seminar Briefing 000146, Office of Health Economics.
  271. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
  272. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
  273. Federico Nutarelli & Massimo Riccaboni & Andrea Morescalchi, 2021. "Product recalls, market size and innovation in the pharmaceutical industry," Papers 2111.15389, arXiv.org.
  274. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  275. Hermans, Raine & Kamien, Morton & Kulvik, Martti & Löffler, Alicia & Shalowitz, Joel (ed.), . "Medical Innovation and Government Intervention," ETLA B, The Research Institute of the Finnish Economy, number 236.
  276. Srivastava, Divya & McGuire, Alistair, 2013. "Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?," LSE Research Online Documents on Economics 54487, London School of Economics and Political Science, LSE Library.
  277. Moshe Levy & Adi Rizansky Nir, 2014. "The Pricing of Breakthrough Drugs: Theory and Policy Implications," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
  278. Ashish Arora & Alfonso Gambardella & Laura Magazzini & Fabio Pammolli, 2009. "A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development," Management Science, INFORMS, vol. 55(10), pages 1638-1653, October.
  279. Magazzini Laura & Fabio Pammolli & Massimo Riccaboni, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT School for Advanced Studies Lucca, revised Jul 2013.
  280. Pamela R. Haunschild & Francisco Polidoro & David Chandler, 2015. "Organizational Oscillation Between Learning and Forgetting: The Dual Role of Serious Errors," Organization Science, INFORMS, vol. 26(6), pages 1682-1701, December.
  281. Katherine Sauer, 2008. "A model of parallel imports of pharmaceuticals with endogenous price controls," Economics Bulletin, AccessEcon, vol. 6(36), pages 1-8.
  282. Sang-Min Park & Nicholas S. Vonortas, 2023. "Translational research: from basic research to regional biomedical entrepreneurship," Small Business Economics, Springer, vol. 60(4), pages 1761-1783, April.
  283. Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
  284. Rutger P. Daems PhD & Edith L. Maes DBA, 2013. "Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics," Working Papers 2013/07, Maastricht School of Management.
  285. Panos Kouvelis & Joseph Milner & Zhili Tian, 2017. "Clinical Trials for New Drug Development: Optimal Investment and Application," Manufacturing & Service Operations Management, INFORMS, vol. 19(3), pages 437-452, July.
  286. Dean Baker, 2006. "The Conservative Nanny State," CEPR Books, Center for Economic and Policy Research (CEPR), number 2006-01.
  287. Tannista Banerjee & Ralph Siebert, 2017. "The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market," Southern Economic Journal, John Wiley & Sons, vol. 84(1), pages 202-228, July.
  288. Fleischhacker, Adam J. & Zhao, Yao, 2011. "Planning for demand failure: A dynamic lot size model for clinical trial supply chains," European Journal of Operational Research, Elsevier, vol. 211(3), pages 496-506, June.
  289. Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B., 2012. "A Reexamination of the Costs of Medical R&D Regulation," Forum for Health Economics & Policy, De Gruyter, vol. 15(2), pages 1-28, October.
  290. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
  291. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
  292. Joseph P Cook, 2014. "Real Option Value and Path Dependence in Oncology Innovation," Seminar Briefing 000077, Office of Health Economics.
  293. Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
  294. Dong Jun Kim & Sun Jung Kim, 2022. "Is Hospital Hospice Service Associated with Efficient Healthcare Utilization in Deceased Lung Cancer Patients? Hospital Charges at Their End of Life," IJERPH, MDPI, vol. 19(22), pages 1-10, November.
  295. Fisher, Jill A. & Cottingham, Marci D. & Kalbaugh, Corey A., 2015. "Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities," Social Science & Medicine, Elsevier, vol. 131(C), pages 322-330.
  296. Mueller-Langer, Frank, 2011. "Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research?," MPRA Paper 40193, University Library of Munich, Germany.
  297. Philip U. Sauré, 2015. "Time-intensive R&D and unbalanced trade," Working Papers 2015-11, Swiss National Bank.
  298. König, Michael D. & Battiston, S. & Napoletano, M. & Schweitzer, F., 2011. "Recombinant knowledge and the evolution of innovation networks," Journal of Economic Behavior & Organization, Elsevier, vol. 79(3), pages 145-164, August.
  299. Charles R. Hulten & Xiaohui Hao, 2008. "What is a Company Really Worth? Intangible Capital and the "Market to Book Value" Puzzle," NBER Working Papers 14548, National Bureau of Economic Research, Inc.
  300. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
  301. Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008. "Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts," Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
  302. Thomas A. Abbott & John A. Vernon, 2007. "The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 293-306.
  303. Colvin, Matthew & Maravelias, Christos T., 2010. "Modeling methods and a branch and cut algorithm for pharmaceutical clinical trial planning using stochastic programming," European Journal of Operational Research, Elsevier, vol. 203(1), pages 205-215, May.
  304. Colvin, Matthew & Maravelias, Christos T., 2011. "R&D pipeline management: Task interdependencies and risk management," European Journal of Operational Research, Elsevier, vol. 215(3), pages 616-628, December.
  305. Mudambi, Ram & Swift, Tim, 2011. "Proactive R&D management and firm growth: A punctuated equilibrium model," Research Policy, Elsevier, vol. 40(3), pages 429-440, April.
  306. Boakye, Derrick & Sarpong, David & Mordi, Chima, 2022. "Regulatory review of new product innovation: Conceptual clarity and future research directions," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
  307. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
  308. Michael Buckley, 2013. "A Constructivist Approach to Business Ethics," Journal of Business Ethics, Springer, vol. 117(4), pages 695-706, November.
  309. Emad Sadoon & Uday Venkatadri & Alireza Ghasemi, 2023. "A Conceptual Framework for Logistics Management and Project Planning in the Clinical Trials Industry," Logistics, MDPI, vol. 7(4), pages 1-42, November.
  310. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  311. Marcello Basili & Roberto Renò & Carlo Zappia, 2005. "Production of a New Drug: A Sequential Investment ProcessUnder Uncertainty," Department of Economics University of Siena 453, Department of Economics, University of Siena.
  312. Hamill, Philip A. & McIlkenny, Philip & Opong, Kwaku K., 2013. "Valuation implications of pharmaceutical companies' R&D regulatory approval notifications," The British Accounting Review, Elsevier, vol. 45(2), pages 99-111.
  313. Gergő Tömöri & Vilmos Lakatos & Bernadett Béresné Mártha, 2021. "The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry," Economies, MDPI, vol. 9(4), pages 1-14, October.
  314. John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
  315. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
  316. Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2011. "Spatial collocation and venture capital in the US biotechnology industry," Research Policy, Elsevier, vol. 40(9), pages 1188-1199.
  317. Mikuláš Luptáčik & Wolfgang Koller & Bernhard Mahlberg & Herwig W. Schneider, 2008. "Growth and Employment Potentials of Chosen Technology Fields," Czech Economic Review, Charles University Prague, Faculty of Social Sciences, Institute of Economic Studies, vol. 2(1), pages 041-075, March.
  318. Christopher Paul Adams & Van Vu Brantner, 2010. "Spending on new drug development," Health Economics, John Wiley & Sons, Ltd., vol. 19(2), pages 130-141, February.
  319. Werner Hölzl & Jürgen Janger & Andreas Reinstaller & Isabel Stadler & Fabian Unterlass & Stephanie Daimer & Thomas Stehnken, 2010. "Barriers to Internationalisation and Growth of EU's Innovative Companies. PRO INNO Europe: INNO-Grips II Report," WIFO Studies, WIFO, number 41059, January.
  320. Atsuko Kamiike, 2020. "The TRIPS Agreement and the Pharmaceutical Industry in India," Journal of Interdisciplinary Economics, , vol. 32(1), pages 95-113, January.
  321. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.